Ranbaxy Laboratories Ltd. (RBXY) rose to its highest in a month after its parent said India’s largest drugmaker aims to start selling the generic version of Pfizer Inc. (PFE)’s cholesterol pill on schedule. Parent Daiichi Sankyo Co., Japan’s second-largest drugmaker, is working with the U.S. Food & Drug Administration to resolve issues related to two of its plants in India, and get an approval to market the drug in the North American nation, spokeswoman Michiko Harada said in an interview today.
